Search Results

You are looking at 31 - 40 of 470 items for :

  • "adjuvant chemotherapy" x
  • Refine by Access: All x
Clear All
Full access

John G. Phillips, Theodore S. Hong, and David P. Ryan

locoregional and distant failure. Chemoradiation is used to lower the rate of local recurrence, and adjuvant chemotherapy is used to lower the rate of both systemic and local recurrence. The initial principles of adjuvant chemotherapy were established before

Full access

Agda Karina Eterovic, Ossama M. Maher, Joya Chandra, Ken Chen, Jason Huse, and Wafik Zaky

in the right cerebellar hemisphere with hydrocephalus ( Figure 1E ). Complete Figure 1. (A) Posttherapy calcification of adrenalectomy and rare viable neuroblastoma cells showing good therapeutic response to adjuvant chemotherapy (hematoxylin

Full access

Prajnan Das, Yixing Jiang, Jeffrey H. Lee, Manoop S. Bhutani, William A. Ross, Paul F. Mansfield, and Jaffer A. Ajani

). In addition, the role of radiation in this disease is being further evaluated. Adjuvant Chemotherapy Adjuvant chemotherapy has not consistently been shown to improve overall survival in gastric cancer; Table 2 summarizes some of the early

Full access

David M. O’Malley

–IV ovarian cancer is the use of maintenance therapy after first-line primary/adjuvant chemotherapy. For patients who achieve a response after platinum-based first-line chemotherapy (± bevacizumab) for advanced disease, olaparib maintenance is a category 1

Full access

Amy A. Kirkham, Karen A. Gelmon, Cheri L. Van Patten, Kelcey A. Bland, Holly Wollmann, Donald C. McKenzie, Taryne Landry, and Kristin L. Campbell

among women receiving adjuvant chemotherapy for early-stage breast cancer who participated in a single-arm intervention trial of structured aerobic and resistance exercise programming compared with a historical cohort of similar patients who did not

Full access

Scott M. Schuetze and Michael E. Ray

adjuvant chemotherapy . Ann Surg 1982 ; 196 : 305 – 315 . 7 Potter DA Kinsella T Glatstein E . High-grade soft tissue sarcomas of the extremities . Cancer 1986 ; 58 : 190 – 205 . 8 Pisters PW Harrison LB Leung DH . Long

Full access

Katya Losk, Ines Vaz-Luis, Kristen Camuso, Rafael Batista, Max Lloyd, Mustafa Tukenmez, Mehra Golshan, Nancy U. Lin, and Craig A. Bunnell

Background Over the past 50 years, substantial reductions in early breast cancer mortality have been documented due to a combination of earlier detection and to advances in adjuvant treatment. 1 – 4 In particular, adjuvant chemotherapy has

Full access

Frank Balis, Daniel M. Green, Clarke Anderson, Shelly Cook, Jasreman Dhillon, Kenneth Gow, Susan Hiniker, Rama Jasty-Rao, Chi Lin, Harold Lovvorn III, Iain MacEwan, Julian Martinez-Agosto, Elizabeth Mullen, Erin S. Murphy, Mark Ranalli, Daniel Rhee, Denise Rokitka, Elisabeth (Lisa) Tracy, Tamara Vern-Gross, Michael F. Walsh, Amy Walz, Jonathan Wickiser, Matthew Zapala, Ryan A. Berardi, and Miranda Hughes

biomarkers, and adverse clinical factors, such as incomplete lung response; these patients are stratified to more intensive therapy with additional chemotherapy agents and RT. Chemotherapy Data show that neoadjuvant and/or adjuvant chemotherapy in

Full access

Rodrigo Goncalves and Ron Bose

clinically for early-stage breast cancer to predict recurrence risk and guide adjuvant chemotherapy decisions. Discuss the role of genome sequencing in breast cancer. Breast cancer is a heterogeneous disease with a wide range of outcomes that are not

Full access

Bonnie S. Glisson and Cesar A. Moran

resection of LCNEC. These data, which are reviewed by Fernandez and Battafarano 24 were from an era before the common use of adjuvant chemotherapy. The rates for 5-year overall survival and for stage I vary widely, from 13% to 57% and 18% to 88